Premium
Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly
Author(s) -
Tsukahara Kappei,
Hata Katsura,
Nakamoto Kazutaka,
Sagane Koji,
Watanabe Naoaki,
Kuromitsu Junro,
Kai Junko,
Tsuchiya Mamiko,
Ohba Fuminori,
Jigami Yoshifumi,
Yoshimatsu Kentaro,
Nagasu Takeshi
Publication year - 2003
Publication title -
molecular microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 247
eISSN - 1365-2958
pISSN - 0950-382X
DOI - 10.1046/j.1365-2958.2003.03481.x
Subject(s) - biology , candida albicans , saccharomyces cerevisiae , cell wall , gene , mutant , cell , phenotype , genetic screen , mutation , genetics , microbiology and biotechnology
Summary Glycosylphosphatidylinositol (GPI)‐anchored cell wall mannoproteins are required for the adhesion of pathogenic fungi, such as Candida albicans , to human epithelium. Small molecular inhibitors of the cell surface presentation of GPI‐anchored mannoproteins would be promising candidate drugs to block the establishment of fungal infections. Here, we describe a medicinal genetics approach to identifying the gene encoding a novel target protein that is required for the localization of GPI‐anchored cell wall mannoproteins. By means of a yeast cell‐based screening procedure, we discovered a compound, 1‐[4‐butylbenzyl]isoquinoline (BIQ), that inhibits cell wall localization of GPI‐anchored mannoproteins in Saccharomyces cerevisiae . Treatment of C. albicans cells with this compound resulted in reduced adherence to a rat intestine epithelial cell monolayer. A previously uncharacterized gene YJL091c , named GWT1 , was cloned as a dosage‐dependent suppressor of the BIQ‐induced phenotypes. GWT1 knock‐out cells showed similar phenotypes to BIQ‐treated wild‐type cells in terms of cell wall structure and transcriptional profiles. Two different mutants resistant to BIQ each contained a single missense mutation in the coding region of the GWT1 gene. These results all suggest that the GWT1 gene product is the primary target of the compound.